Cases & Deals

Novexel acquired by AstraZeneca for $505 million

Clients Novexel SA

Jones Day represented Novexel SA in its $505 million acquisition by AstraZeneca PLC. The deal centered on Novexel's two most advanced drug programs, CAZ104 and CEF104, which are in development to treat bugs that have gained resistance to existing antibiotics, a trend that is spurring research into new anti-infective medicines.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.